Triolab AB appointed exclusive distributor in Sweden for Sienna’s hTERT test as well as future products in the portfolio.
MELBOURNE: Sienna Cancer Diagnostics announced the appointment of Triolab AB as its exclusive distributor in Sweden.
The distribution agreement grants Triolab AB the right to sell Sienna’s hTERT product to Swedish pathology laboratories where it can be used as an adjunct in urine cytology assisting pathologists in their diagnosis of bladder cancer, of which there are approximately 2,400 new cases diagnosed annually.
Triolab AB is a subsidiary of AddLife, a leading independent distributor to the European life sciences market with a focus on niche products in laboratory analysis and medical technology. Sales occur in approximately 25 countries, primarily in the Nordic region, Central Europe and Eastern Europe.
Vice Managing Director of Triolab AB, Anna Bergstrom, said: “We are very happy to sign this agreement with Sienna Cancer Diagnostics. It gives us the opportunity to provide our customers with a new, innovative and accurate test to find bladder cancer at an early stage. Our vision is to be ‘The leading partner within the laboratory diagnostics market’. To be able to fulfill this we continually look for partners with innovative and high-quality products, which Sienna is. We look forward to cooperating with a partner that shares our goal to improve cancer diagnostics.”
Triolab joins Immuno Diagnostics Oy, recently appointed as exclusive distributor in Finland, as the second AddLife company to be appointed in the region. Sales, marketing, and technical support training will now commence with Triolab staff. Unilabs, a commercial laboratory in Sweden, is currently evaluating the hTERT test for routine use. Triolab takes over distribution in this region from Axlab A/S. Triolab, the exclusive distribution partner for Leica Biosystems in Sweden, has extensive pathology industry sales and technical support experience and will make an ideal distribution partner for Sienna.
Sienna’s Business Development Manager, Minesh Lalla, said: “The Sienna team is making excellent progress with our hTERT IVD growth strategy. Triolab joins Zotal Ltd (Israel) and Scientle Innovations (New Zealand) as recently appointed distribution partners. Triolab’ s Anna Bergstrom, and Group Manager Pathology, Aseel Albayati, have been engaged and enthusiastic about the opportunity Sienna’s hTERT ICC test presents from our very first meeting at their offices in Solna. Triolab brings a wealth of experience in the Swedish pathology market and we believe that with their market reach we can build on the progress we have made with Axlab. Sienna continues to increase its European presence in 2020 with its extensive due-diligence providing multiple growth opportunities.”
